17,261 trials
Cytokine Release Syndrome
Primary: Percentage of Participants Who Developed ≥Grade 2 Cytokine Release Syndrome (CRS) by Day 14 After Immune Effector Cell (IEC) Therapy, Assessed by Using American Society…
Acute Myeloid Leukemia or Myelodysplastic Syndromes
Primary: To Assess Relapse-free Survival (RFS) in Patients With TP53 Mutated AML or MDS After Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HSCT). — 12.5 months
Congenital Heart Defects
Primary: S-creatinine — 23.9; 25.9; 33.7; 34.2 μmol/L — p=0.45
Neuroendocrine Tumors · Neuroendocrine Carcinoma · Neuroendocrine Cancer
Primary: Objective Radiographic Response Rate (ORR) — .1 proportion of participants
B-Lymphoid Malignancies · Acute Lymphocytic Leukemia · Chronic Lymphocytic Leukemia
Primary: Number of Events That Was Grade 3-4 Toxicities — 4; 1; 22; 1 events
Esophageal Cancer
Primary: Number of Subjects Reporting Treatment Emergent Adverse Events (TEAEs) — 12; 5; 21; 11 Participants
Alveolar Bone Resorption · Sequela · Tooth Extrusion
Primary: Bone Density - Limited View CBCT (Cone-beam Computed Tomography) Measurements — 14.4; 1.5 percentage of bone height shrinkage
Cholinergic Urticaria
Primary: Change From Baseline in Post-provocation Urticaria Activity Score (UASprovo) — -1.1; -0.5 scores on a scale — p=0.277
Chronic Kidney Diseases · Hypertension
Primary: Systolic Blood Pressure — 155.8; 154.3; 155.7; 150.4 mmHg
Acute Myeloid Leukemia
Primary: Response Rate of Crenolanib Besylate Combination Therapy — 2; 0; 3; 1 Participants
Cholangiocarcinoma · Urothelial Cancer · Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors
Primary: Phase 1: Dose Escalation-Maximum Tolerated Dose (MTD) — NA; 20 Milligrams
Carcinoma, Non-Small-Cell Lung
Primary: Overall Response Rate (ORR) by Blinded Independent Review Committee (BIRC) Assessment — 29.0; 11.9; 9.3; 6.7 Percentage of Participants
Loss of Chromosome 17p · Recurrent Chronic Lymphocytic Leukemia · Recurrent Small Lymphocytic Lymphoma
Primary: Number of Participants With a Response for Cohorts 1 and 3 — 5; 10 Participants
Healthy Volunteer Study
Primary: Dose Response of Intravenous Oxytocin on Sustained Heat Pain — 3.1; 2.9; 3.1; 2.9 units on a scale — p=<0.05
Non-Hodgkin Lymphoma
Primary: Overall Response Rate (ORR) as Determined by Local Investigator — 32.1 Percentage of participants